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Sex hormone-binding globulin (SHBG) is the high-affinity binding protein for androgens and estrogens. 
According to the free hormone hypothesis, SHBG modulates the bioactivity of sex steroids by limiting 
their diffusion into target tissues. Still, the in vivo physiological role of circulating SHBG remains 
unclear, especially since mice and rats lack circulating SHBG post-natally. To test the free hormone 
hypothesis in vivo, we examined total and free sex steroid concentrations and bioactivity on target 
organs in mice expressing a human SHBG transgene. SHBG increased total androgen and estrogen 
concentrations via hypothalamic-pituitary feedback regulation and prolonged ligand half-life. Despite 
markedly raised total sex steroid concentrations, free testosterone was unaffected while sex steroid 
bioactivity on male and female reproductive organs was attenuated. This occurred via a ligand-
dependent, genotype-independent mechanism according to in vitro seminal vesicle organ cultures. 
These results provide compelling support for the determination of free or bioavailable sex steroid 
concentrations in medicine, and clarify important comparative differences between translational mouse 
models and human endocrinology.
A central dogma in endocrinology, the so-called “free hormone hypothesis”, states that the biological activity of 
hormones is determined by their free (i.e. non-protein-bound) concentrations1. In the case of androgens and 
estrogens, free hormone concentrations and bioactivity are believed to be determined by sex hormone-binding 
globulin (SHBG)2. SHBG is a liver-secreted homodimeric glycoprotein with high affinity (nM Kd) for dihydrotes-
tosterone (DHT), testosterone (T) and, to somewhat lesser extent, 17β -estradiol (E2)3. Androgens and estrogens 
are key regulators of reproductive organs as well as other sexually dimorphic tissues like muscle, adipose tissue 
and bone4. T can directly, or indirectly following conversion into DHT, act via the androgen receptor (AR), or via 
estrogen receptors (ERα and β ) following aromatization of T into E2. In normal adults about 55% of T in men or 
E2 in women is bound to circulating SHBG. The remainder is loosely bound to bulk carrier proteins like albumin 
and only 1–3% of sex steroids normally circulate freely5. In clinical practice, free sex steroid concentrations are 
calculated from total sex steroid, albumin and SHBG concentrations, or measured directly using equilibrium 
dialysis or other methods6,7.
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Despite widespread adoption of the free hormone hypothesis, it remains unclear whether total or free sex 
steroids are the most clinically useful measurement5,8. More importantly, experimental validation of the free 
hormone hypothesis in sex steroid biology remains scanty. In addition to the general belief that SHBG sup-
presses sex steroid bioactivity, several additional effects of SHBG have been proposed. Foremost among these 
are ligand-independent effects, actions of liganded SHBG via a membrane receptor or endocytosis, paradoxical 
prevention of sex steroid deficiency due to increased circulating ligand half-life (and thus availability), and regu-
lation of the androgen/estrogen ratio9–11. Others have argued that higher levels of SHBG are compensated in vivo 
by hypothalamic-pituitary feedback, resulting in higher total sex steroid concentrations12. This results in great 
confusion and continuing debate over whether —and by which mechanisms— SHBG regulates total, free and/or 
bioavailable sex steroid concentrations and their physiological responses11–14.
These unanswered questions bear clinical relevance because SHBG concentrations fluctuate across the 
lifespan, are influenced by gender or drugs and have been associated with diseases including type 2 diabetes and 
metabolic syndrome, osteoporosis, reproductive disorders etc.15–17. Notably, several epidemiological studies have 
even suggested effects of SHBG independent from total or free sex hormone concentrations16,18. However, since 
SHBG concentrations are a sensitive indicator of metabolic status19,20, debate persists as to whether decreased 
SHBG and/or low T levels are a biomarker rather than a cause of disease21–23.
An SHBG homologue known as the androgen-binding protein is expressed locally in the testis of mice and 
rats but hepatic Shbg expression and secretion is lacking postnatally in these rodent models. Therefore a mouse 
model expressing a human SHBG transgene (SHBG-Tg) has been established previously24. Hitherto it has been 
used almost exclusively to study regulation of human SHBG expression in vivo19,20,25. Conversely, lack of circulat-
ing SHBG was found to explain why mice have remarkably low and highly fluctuating total T serum concentra-
tions4,24, but otherwise no reproductive or other phenotypic effect of SHBG has yet been ascertained.
There is increasing awareness that reliable sex steroid measurements require mass spectrometry rather than 
immunoassays, not only in humans but also in rodent models26–28. This is especially the case for E2, the serum 
level of which has even been reported to be undetectable in male mice in recent mass spectrometry-based stud-
ies26, 28. This virtual absence of circulating E2 in male mice has been used previously to criticize the ubiquitous use 
of male mice as models to study the effects of gender or sex steroids on chronic diseases like diabetes, osteoporosis 
etc.4. In the present study, we used the SHBG-Tg mouse model in combination with liquid chromatography tan-
dem mass spectrometry (LC-MS/MS) methods to determine how, and by which mechanisms, SHBG influences 
circulating total and free sex steroid concentrations and their physiological effects on various target tissues (repro-
ductive organs, muscle and bone mass, and glucose metabolism).
Results
SHBG increases circulating total concentrations of androgens, estrogens and their precur-
sors. SHBG serum concentrations in SHBG-Tg mice are shown in Fig. 1A (in WT mice, SHBG was undetect-
able, < 1 nmol/L). SHBG levels increased with age in each gender but more so in males, and the sex difference was 
significant at 12 weeks of age. Hepatic expression of human SHBG was also higher in male than female SHBG-Tg 
mice (Fig. 1B). At 24 weeks of age, steroid hormone profiling of serum and urine by LC-MS/MS revealed that 
male SHBG-Tg mice have increased total serum concentrations of T and DHT (~200-fold), as well as several of 
their precursors (or metabolites) like pregnenolone, dehydroepiandrosterone (DHEA), androstenedione, andros-
terone/etiocholanolone and 5α - or 5β -androstane-3β ,17β -diol (Fig. 1C). WT male mice (n = 5) had undetectable 
E2 concentrations whereas in SHBG-Tg males (n = 5), two had detectable circulating E2. In contrast, urinary 
concentrations of T or androstenedione, as well as conjugation products like estradiol-3-sulphate and 5α -andros-
tane-3β , 17β -diol-3-glucuronide were unaffected. Progesterone or corticosterone levels in serum or urine were 
not different between WT and SHBG-Tg littermates. A similar profile was observed in 24-week-old female mice 
(unselected for estrous cycle phase) (Fig. S1A). Using a more sensitive, dedicated LC-MS/MS method29, E2 was 
undetectable in WT male mice, whereas in SHBG-Tg males (n = 9), values above the limit of quantification 
(1.3 pg/mL) were observed in four of them (Fig. 1D). These low to undetectable values could not be attributed to 
the known fluctuating T concentrations in male mice30, as shown by the consistent lack of E2 in WT mice with 
a s.c. continuous-release T implant (Fig. 1D). The lack of E2 was also not due to limitations of the LC-MS/MS 
method, as shown in castrated SHBG-Tg males with s.c. silicone E2 implants, or female mice (Fig. 1E). E2 con-
centrations measured randomly in the estrous cycle were increased in female SHBG-Tg vs. WT mice (Fig. 1E). 
These differences are summarized schematically along with a diagram of murine steroid metabolism in Fig. S1B.
Male SHBG-Tg mice display a mild hypogonadal phenotype. Despite the higher total T concentra-
tions in SHBG-Tg mice, their free T concentrations measured directly by equilibrium dialysis coupled to LC-MS/
MS were unaltered (Fig. 2A,B). However, serum luteinizing hormone (LH) concentrations were increased in 
SHBG-Tg male mice (Fig. 2C). To confirm that the latter hypothalamic-pituitary feedback regulation normalized 
the free T concentrations, SHBG-Tg mice were castrated and given T implants. Under these conditions, free T 
levels were decreased in SHBG-Tg males (Fig. 2D). The weight of the most androgen-sensitive organs (seminal 
vesicles (SV) and levator ani/bulbocavernosus [LA/BC] muscles) was decreased at 24 weeks of age (Fig. 2E,F). 
Body weight was not different between SHBG-Tg and WT mice at any age (Fig. S2A). The decrease in SV and 
LA/BC muscle weights was evident as early as 9 weeks of age (late puberty) (Fig. S2B,D). The difference in SV 
weight was entirely attributable to lower SV fluid content (Fig. S2C). The anogenital distance, which is greater in 
male compared to female mice due to androgen effects, was not influenced by SHBG at 3, 6, 9 or 12 weeks of age 
(Fig. S2E). Lean body mass, fat mass or bone mineral density by DXA, as well as the response to an i.p. glucose or 
insulin tolerance test at 24 weeks, showed gender differences as expected, which however did not differ by SHBG 
genotype (Fig. S3A–F).
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Figure 1. Endocrine profile of SHBG-Tg mice. (A) Human SHBG serum concentrations (shown as mean 
± SD) in male and female SHBG-Tg mice of different ages (n = 7–10 per gender and age except 24-week-
old females, n = 3). ****P < 0.0001 vs. female SHBG-Tg mice of same age group. +P < 0.05, ++P < 0.01, 
++++P < 0.0001 vs. 3-week-old mice of same gender. (B) Human SHBG expression (relative to mouse 18S) in 
livers of female and male WT and SHBG-Tg mice (n = 3 for WT and n = 5 for SHBG-Tg mice of each gender). 
***P = 0.0002 for difference between SHBG-Tg females and males. (C) Concentrations in serum (left from 
vertical dotted line) and urine (right from vertical dotted line) of selected steroid hormones in 24-week-old 
WT and SHBG-Tg male mice (n = 5 per group). *P < 0.05 vs. WT mice. (D) Serum E2 in 12-week-old WT 
and SHBG-Tg male mice, either sham-operated and given empty placebo implants, or orchidectomized with 
continuous-release s.c. T replacement. The limit of quantification (LOQ) of the LC-MS/MS method (1.3 pg/mL) 
is indicated by the horizontal dotted line. *P < 0.05, n as indicated by individual replicates in each group. (E) 
Serum E2 in 12-week-old orchidectomized male mice given s.c. undiluted E2 implants of different lengths as 
indicated, or female WT and SHBG-Tg mice. The limit of quantification (LOQ) of the LC-MS/MS method 
(1.3 pg/mL) is indicated by the horizontal dotted line. ****P < 0.0001, n as indicated by individual replicates in 
each group.
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To investigate whether the reduced SV weight was due to an intrinsic, genotype-dependent developmental 
deficit or an endocrine mechanism, we performed organ cultures. SVs dissected from day 0–1 postnatal mice 
showed no morphologic differences at baseline between WT and SHBG-Tg mice (data not shown). After three 
days, either 1nM of DHT or mibolerone (a potent synthetic AR agonist) stimulated branching morphogenesis, 
regardless of donor mouse genotype (Fig. 3A,B,D). Compared to control medium, SHBG-containing medium 
suppressed the induction of epithelial folding by DHT (Fig. 3C), but not by mibolerone (which has negligible 
affinity for SHBG) (Fig. 3E).
SHBG protects against male and female reproductive organ hypertrophy. Next, we investi-
gated the response of SHBG-Tg and WT mice to castration and androgen replacement. In castrated mice with 
s.c. T or DHT implants, SV hypertrophy was prevented in SHBG-Tg compared to WT males (Fig. 4A). The 
hypertrophic response of LA/BC muscles was however unaffected (Fig. 4B). There were no differences in the 
weight of SVs or LA/BC muscle in castrated SHBG-Tg vs. WT mice. In ovariectomized mice, uterus weights were 
not different between WT and SHBG-Tg females. However, the effect of both E2 and DHT31 on uterus weight 
was less pronounced in SHBG-Tg females (Fig. 4C), despite the fact that total E2 concentrations were higher in 
OVX+ E2-treated SHBG-Tg than WT female mice (Fig. 4D). Under basal conditions however, randomly cycling 
24-week-old female mice displayed no difference in uterus weight (Fig. S2F).
Figure 2. Evidence of hypogonadism in 24-week-old male SHBG-Tg mice. (A,B) Serum total and free T. 
n = 5 biological replicates per group (to obtain sufficient volume, sera of 2 mice were pooled if necessary). 
**P < 0.01 (C) Serum luteinizing hormone (n = 7–9 per group). *P < 0.05. (D) Free T by equilibrium dialysis in 
WT and SHBG-Tg mice which were orchidectomized and given s.c. T replacement (ORX+ T). n = 4 per group, 
*P < 0.05. (E,F) Seminal vesicle and levator ani/bulbocavernosus complex (LA/BC) muscle weights. Individual 
replicates, mean ± SEM are shown. ***P < 0.001, ****P < 0.0001.
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SHBG increases the half-life of circulating ligands and prevents their entry into target tissues. 
A single i.v. injection of tritium-labeled DHT, T and mibolerone into castrated mice revealed that SHBG pro-
longed the half-life of the tracer signal following DHT and T but not mibolerone injection (Fig. 5A–C). To further 
exclude the possibility of confounding by tracer catabolism, the experiment was repeated using unlabeled T. 
Total T peak concentrations measured by LC-MS/MS were ~20-fold increased eight minutes after i.v. injection 
of SHBG-Tg mice. After 60 minutes, T in WT mice was 74% lower compared to the eight minute time point, 
whereas SHBG-Tg mice showed a non-significant 28% T decrease (Fig. 5D).
To reconcile the undetectable circulating E2 in WT and very low circulating E2 concentrations in 
SHBG-Tg male mice with the well known physiological effects of estrogens in male mice and the presence of 
estradiol-3-sulphate in urine, we investigated local E2 concentrations within a classical target tissue like bone. 
Homogenates from appendicular bone of mice with s.c. T implants (see Fig. 4A,B, ORX+ T group) revealed 
clear intraskeletal concentrations of E2 in all mice, despite undetectable circulating E2 in all these animals. 
Furthermore, intraskeletal E2 was lower in SHBG-Tg than in WT males (Fig. 5E), while Cyp19a1 expression 
was unaffected (Fig. 5F). However, no clear bone phenotype could be discerned under basal conditions in 
24-week-old mice (Fig. S4A–F).
Discussion
Our findings provide for the first time clear experimental validation of the free hormone hypothesis with respect 
to sex steroids, i.e. that SHBG-bound T in the circulation is restricted from entering into target tissues and elicit-
ing its physiological functions in vivo. Unexpectedly however, the most striking effect of SHBG is not to decrease 
free T concentrations, but to increase total androgen and estrogen concentrations (Fig. 1). This occurs via at least 
two mechanisms: hypothalamic-pituitary feedback stimulation (as evidenced by increased LH and concentra-
tions of precursor androgens which themselves do not bind to SHBG) and increased circulating ligand half-life 
Figure 3. Effect of SHBG on androgen-induced branching morphogenesis in seminal vesicle organ 
cultures. For each genotype, two representative microphotographs at day 3 of culture are displayed. All pictures 
scaled identically (1 mm scale bar shown in first photograph only). (A) Unstimulated condition showing lack of 
epithelial folding in the absence of androgens. (B) Induction of branching morphogenesis (arrowheads in two 
panels) by 1 nM DHT in both genotypes. (C) Suppression of DHT-induced branching morphogenesis by SHBG 
in the media. (D) Induction of epithelial folding by 1 nM mibolerone in both genotypes. (E) Lack of suppression 
of mibolerone-induced branching morphogenesis by SHBG.
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(Fig. 5A–D). This feedback regulation normalized free T levels in response to differences in circulating SHBG, 
resulting in only minimal residual suppression of androgen bioactivity evident only in the most sensitive organs 
(SVs and LA/BC muscles) under basal conditions.
The conclusion that SHBG increases total but decreases bioactive sex steroid concentrations is in line with 
human genetic evidence. A genome-wide association meta-analysis identified a functional SHBG polymorphism 
(rs6258) which decreased total and increased free T levels in adult men13. One man with undetectable SHBG 
also had very low total but normal free T levels32. Although measured free T was not significantly different in 
SHBG-Tg male mice (Fig. 2B), this represents only one time point which could have been confounded by the 
known highly fluctuating, spiking T concentrations in male mice30. The somewhat wider distribution of free T 
in WT mice and the difference in free T in mice given a continuous-release s.c. T implant (Fig. 2D) supports this 
possibility.
In humans, protection from endogenous or exogenous androgen excess is thought to be a key physiological 
function of SHBG. For example, low SHBG may reinforce the hirsutism of obese women with polycystic ovary 
syndrome33 while frank virilization from fetal androgens has been observed in a woman with genetic SHBG 
deficiency34,35. A similar role in protecting against hormone excess has been demonstrated for other binding 
proteins36, and our findings in orchidectomized and ovariectomized mice treated with T or DHT support this 
possibility.
Interestingly, SHBG prevented SV hypertrophy but did not interfere with the hypertrophic response of the 
androgen-sensitive LA/BC muscles (Fig. 4B), which resembles the effect of a selective androgen-receptor mod-
ulator (SARM)37. Because T treatment in older men may adversely affect reproductive tissues like the prostate, 
alternative treatment strategies are needed. The free hormone hypothesis acknowledges that the effect of binding 
proteins may differ between tissues depending on their vascularity, blood flow rate or lipid composition, for 
example1,15. Besides differences in tissue characteristics, a possible explanation for this SARM-like effect is that 
SHBG has the highest affinity for DHT, which is a crucial mediator of androgen effects on reproductive but 
not other organs38. However, further investigation is needed to confirm whether SHBG truly has tissue-specific 
effects, and whether SHBG concentrations also modulate the response to T therapy in humans.
In any case, a trade-off of this protection against hyperstimulation was mild hypogonadism under basal con-
ditions, which was evident only in the most sensitive target organs (SV and LA/BC muscle weights, Fig. 2E,F). 
This is consistent with our recent finding that men with high SHBG but normal total T may still have symptoms 
and signs consistent with late-onset male hypogonadism39. Importantly however, the high SHBG concentrations 
in SHBG-Tg mice had no effects on less androgen-sensitive outcomes like body composition, bone or glucose 
metabolism, suggesting that the numerous epidemiological studies suggesting this possibility15,16,18 may suffer 
Figure 4. SHBG inhibits the stimulatory effects of sex steroids on male and female reproductive organs. 
(A,B) Seminal vesicle and LA/BC muscle weight of 12-week-old WT and SHBG-Tg mice following 3 weeks of 
orchidectomy (ORX), with placebo, testosterone (ORX+ T) or DHT replacement (ORX+ DHT). n = 5–10 for 
each genotype and treatment group. ****P < 0.0001 compared to ORX in same genotype. ++++P < 0.0001 vs. 
WT in same treatment group. (C) Uterus weight of female WT or SHBG-Tg mice following ovariectomy (OVX) 
with either placebo, E2 (diluted 1/16 w/w with cholesterol) replacement (OVX+ E2) or DHT replacement 
(OVX+ DHT) replacement between 18 and 20 weeks of age, respectively. n = 5–14 per group. (D) Serum E2 
concentrations in WT and SHBG-Tg following OVX+ E2 replacement (n = 6 randomly selected mice per 
group). **P  < 0.01 vs. WT by Mann-Whitney U test.
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from residual confounding by metabolic status19,40,41. These findings are in line with another recent study showing 
that obesity-induced metabolic derangements regulate hepatic SHBG expression, whereas SHBG itself did not 
prevent the metabolic consequences of obesity41. We also found no phenotypic evidence for ligand-independent 
effects of SHBG, since no differences were seen in gonadectomized or pre-pubertal animals.
Finally, several important lessons for laboratory animal sciences can be drawn from our results. First, our find-
ings reinforce the notion that reproductive organ weights are more reliable indicators of sex steroid status than 
circulating sex steroid concentrations in mice and rats (species which lack circulating SHBG)4. In other words, 
total T levels are lower in male mice compared to humans not because lab mice are hypogonadal30, but because 
of lack of circulating SHBG. The results in SHBG-Tg mice also unambiguously demonstrate the presence of cir-
culating precursor androgens like DHEA, despite lower adrenal sex steroid production in rodents compared to 
humans42,43. Further misinterpretation of rodent endocrinology derives from reliance on immunoassays30 rather 
than mass spectrometry to measure very low concentrated analytes27,28. Thirdly, we show that even in SHBG-Tg 
male mice circulating E2 is very low (compared to humans or female mice). These findings should however 
be interpreted with caution because even in SHBG-Tg mice, the serum E2 concentrations were either below 
or only slightly above the limit of quantification (LOQ) of our method. Nevertheless, these results support the 
Figure 5. Effects of SHBG on sex steroid pharmacokinetics and biodistribution. (A) Half-life of tritium-
labeled DHT following i.v. injection. n = 4–9 per group. **P < 0.01. (B) Half-life of tritium-labeled T following 
i.v. injection. n = 3–6 per group. *P < 0.05. (C) Half-life of tritium-labeled mibolerone following i.v. injection. 
n = 6–10 per group. (D) Testosterone concentrations at 8 or 60 minutes following i.v. T injection. n = 6–10 
per group. **P < 0.01 compared to 8 minute timepoint in same genotype. (E) Concentration of E2 in bone 
homogenates. n = 4 per group. *P < 0.05. (F) Relative mRNA expression of mouse aromatase (Cyp19a1) in the 
bones (tibia and femur) of 24-week-old WT and SHBG-Tg male mice. n = 9–11 per group.
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conclusions that lack of detectable circulating E2 in male mice is not due to fluctuating T concentrations and only 
partially explained by lack of SHBG. Still, estrogen conjugation products were clearly present in urine and E2 has 
well established physiological effects in male target organs like bone4. We reasoned that, contrary to the situation 
in humans where circulating E2 derives predominantly from aromatization in peripheral adipose tissues44, E2 in 
mice probably derives mainly from local aromatization within target tissues (Fig. 6). Indeed, mice are known to 
have low aromatase expression in adipose tissue45. Our hypothesis was supported by demonstrating higher intras-
keletal than circulating E2 in castrated, T-treated mice of both genotypes, with lower concentrations in SHBG-Tg 
compared to WT animals (Fig. 5E). The difference in intraskeletal E2 concentrations between genotypes could 
not be attributed to altered aromatase (Cyp19a1) gene expression (Fig. 5F) and is therefore likely explained by the 
fact that SHBG restricts the bioavailability of T. However, it should be noted that aromatase expression was very 
low in bones of both WT and SHBG-Tg mice, in line with previous studies46. Further work is therefore needed 
to examine whether intraskeletal E2 truly derives from local aromatization within bone, or from an endocrine 
mechanism whereby it is aromatized in other nearby or distant tissues with subsequent rapid uptake into bone 
and clearance from the serum due to lack of SHBG. In any case, given that E2 replacement almost inevitably pro-
duces supraphysiological E2 concentrations in male mice (Fig. 1C), we caution against deriving physiologically 
relevant conclusions from such an approach. Finally, it should be noted that serum SHBG concentrations are 
higher in SHBG-Tg mice compared to humans25. Moreover, we observed an age-related increase in both genders 
but more so in male SHBG-Tg mice, similar to previous findings25. In humans however, men have higher, lower 
and similar SHBG concentrations compared to women before puberty, after puberty and in old age, respec-
tively15. Explaining the age- and gender-specific differences in SHBG concentrations and transgene expression in 
SHBG-Tg mice was not the aim of our study, but previous studies found little evidence that sex steroids directly 
Figure 6. Summary of differences in sex steroid endocrinology between men and mice. (A) In men, 
circulating androgens are derived from the testes and adrenals. Circulating E2 is estimated to be ~85% derived 
from aromatization in peripheral adipose tissues, with the remainder secreted directly from the testis. SHBG 
binds androgens as well as estrogens and prevents their entry into target tissues (indicated by striped arrows). 
Within target tissues, T can also be converted locally into E2. Conjugation and feedback regulation occur 
within tissues and thus at the level of the free/bioactive sex steroids. Water-soluble conjugation products are 
removed by hepatic and renal clearance. (B) In contrast, male mice have lower androgen and undetectable E2 
concentrations due to (a) less pronounced adrenal secretion of precursor steroids, (b) possibly due to markedly 
lower peripheral aromatization due to absence in mice of the alternative promoter which drives peripheral 
CYP19A1 expression in humans, and (c) lack of SHBG, which facilitates rapid entry of both sex steroids into 
target tissues. Thus, estrogens act mainly as local hormones in target tissues of male mice. Lower gonadotropin 
concentrations in male mice are at least in part due to lack of SHBG.
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regulate hepatic SHBG expression and secretion in SHBG-Tg mice25. Thus, investigation into the indirect effects 
of age and gender via other e.g. metabolism-related transcription factors may be required20,47.
In summary, our detailed examination of the SHBG-Tg model reveals that contrary to the general miscon-
ception that SHBG decreases free T concentrations, in vivo it mainly increases total androgen and estrogen 
concentrations (via hypothalamic-pituitary feedback and prolonged circulating half-life). Nevertheless, SHBG 
attenuated androgen bioactivity resulting in mild hypogonadal signs in reproductive organs, but no major phe-
notypic effects on other sexually dimorphic target tissues. These findings offer empirical support for measuring 
free or bioavailable T in clinical practice, since SHBG can clearly confound interpretations based on circulat-
ing total sex steroid concentrations. Although we found no evidence that SHBG has ligand-independent effects 
in vivo, alternative mechanisms of action beyond the regulation of sex steroid plasma transport may still contrib-
ute to effects on certain organs9,10. Finally, our study may assist in the appropriate use of male mouse models for 
translational biomedical research.
Methods
SHBG-Tg mice. Heterozygous SHBG(4.3kb)+/− mice (SHBG-Tg)24 and WT littermate controls were housed in 
conventional facilities. Presence of the transgene was confirmed by PCR on tail DNA using previously described 
primer pairs47. Mice were backcrossed for eight generations to obtain an incipient congenic (> 99.5%) C57BL/6J 
background confirmed by a Jax 1500 SNP panel (n = 2 mice). The KU Leuven animal ethics committee approved 
all procedures (P028/2012). Animals were bred and all experimental methods were performed in accordance with 
the Belgian national regulations for Animal Welfare and the 2010/63/EU directive. For ex vivo analyses, animals 
were euthanized by cardiac puncture following pentobarbital anesthesia. Tissues were dissected and wet weight 
measured. SVs were weighed before and after manual expression of SV fluid.
Surgical procedures. Mice were anesthetized by i.p. ketamin-xylazine (100/25 μ g/kg) or isoflurane anesthe-
sia and given 60 μ g/kg buprenorphine analgesia. Orchidectomy and ovariectomy were performed via suprapu-
bic and bilateral flank incisions. Implants of medical-grade silicone tubing (Silclear, Degania Medical, Degania, 
Israel) sealed with medical adhesive silicone (Silastic, Biesterfeld, Germany) were implanted in the nuchal region, 
either empty (placebo) or filled with T, DHT or various doses of E2 (all from Sigma-Aldrich, St. Louis, MO, 
USA). Mice were operated at 9 weeks of age and ex vivo analyses were performed at 12 weeks of age unless noted 
otherwise.
Serum analyses. Cardiac or tail blood was collected in Eppendorf or Microvette serum tubes (Sarstedt, 
Nümbrecht, Germany) respectively, left to clot at room temperature for > 1 h and centrifuged twice at 10, 000 g 
for 5 minutes according to manufacturer instructions. Human SHBG concentrations were measured on a Roche 
Modular E clinical immunoassay platform. Mouse LH was measured at Türkü Center for Disease Modeling 
with a supersensitive immunofluorometric assay as described48. Osteocalcin was measured by an in-house 
radioimmunoassay49.
Mass spectrometry and equilibrium dialysis. Total T and E2 were measured at the University Hospitals 
Leuven by LC-MS/MS without derivatization using a two-dimensional chromatography system and an AB/Sciex 
QTrap 5500 tandem mass spectrometer in atmospheric pressure chemical ionization positive (APCI) and elec-
trospray ionization (ESI) negative ion mode, respectively, as described29 (and Antonio et al., manuscript in prep.).
Endogenous steroid hormone profiling was performed at Waegeningen RU by an UPLC-MS/MS method in 
analogy with a previous reported method50 (and Blokland et al., manuscript in preparation). Solid phase extrac-
tion of aglycons and sulphate/glucuronide conjugates was achieved using Oasis HLB and WAX 96-well plates, 
respectively, followed by derivatization of aglycons with picolinic acid. Aglycons and conjugates were chroma-
tographically separated on BEH and CSH C18 columns respectively, and analyzed separately on a Xevo TQ-S 
mass spectrometer (Waters Corp., Milford, MA, USA) in ESI mode switching between positive and negative ion 
selection mode.
Total T as well as free T after equilibrium dialysis were measured at the University Hospital of Ghent by 
LC-MS/MS using an AB/Sciex QTrap 5500 tandem mass spectrometer in APCI mode as described51. Briefly, free 
T was directly measured by LC-MS/MS in the dialysate, after overnight equilibrium dialysis of 500 μ L serum at 
37 °C using Fast Micro-Equilibrium dialyzer cartridges with regenerated cellulose 25 kD membranes (Harvard 
Apparatus; Holliston, USA). Total interassay CV for direct measurement of free T by equilibrium dialysis coupled 
to LC-MS/MS is 8%.
Neonatal seminal vesicle cultures. Neonatal SV cultures were performed according to52 with some mod-
ifications (G. Cunha, personal communication). Left and right SVs were dissected from postnatal day 0–1 pups 
and incubated for 3 days at 37 °C, 5% CO2 and 100% humidity in 96-well plates (Greiner bio-one, Frickenhausen, 
Germany) with 50 μ L of DMEM/F12 media with insulin (10 mg/L), transferrin (5.5 mg/L) and selenium (6.7 ng/L) 
(ThermoFisher Scientific (Waltham, MA, USA). DHT, mibolerone (Toronto Research Chemicals, Ontario, 
Canada) or vehicle were added in 1:1000 dilutions with or without 60 nmol/L SHBG from conditioned media 
obtained by transfecting HEK293-cells with a human SHBG or empty pRC/CMV vector3. Transfected cell media 
were then concentrated by centrifugal ultrafiltration using Amicon Ultracel tubes with a 30 K molecular weight 
cut-off (Merck, Darmstadt, Germany).
In vivo pharmacokinetics. Tritium-labeled DHT, T and mibolerone (Perkin-Elmer, Waltham, MA, USA) 
or unlabeled T (Sigma-Aldrich, St. Louis, MO, USA) were added to 50 μ L of autologous serum of each mouse, 
incubated for > 30 minutes and injected via the lateral tail vein. Tailbleeding was performed at several timepoints, 
for each of which 10 μ L of serum was dissolved in 3 mL of UltimaGold scintillation cocktail and analyzed on a 
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Tri-Carb 2810 TR liquid scintillation counter (Perkin-Elmer, Waltham, MA, USA). Half-life was estimated as the 
first timepoint at which the tracer signal was > 50% below peak values in each animal. Unlabeled T was analyzed 
in serum obtained from cardiac puncture by in-house LC-MS/MS as described above.
Quantitative PCR. Total RNA was extracted from livers as well as left tibias and femurs of 24-week-old 
mice using TRIzol reagent (Invitrogen), according to the manufacturer’s protocols. After digestion with DNase I 
(Qiagen, Antwerp, Belgium), cDNA was synthesized from 1 μ g RNA using the RevertAid M-MuLV Reverse 
Transcriptase kit (Fermentas, St Leon-Rot, Germany) and random hexamer primers (Fermentas). The PCR 
reaction mixtures (10 μ l) contained 1× Fast SYBR Green qPCR Master mix (ThermoFisher Scientific) and 
0.15 μ L (2.5 μ M) of each primer. The StepOne Plus Real-Time PCR system (Applied Biosystems, Foster City, 
CA, USA) was used. The primers used were: human SHBG-Fw 5′ -ATCACAAAAACCTCCTCCTCCTT-3′. 
SHB G-Rev 5 ′ -ATCTCCCATCATCCAGCCGT-3 ′   (190 Bp amplicon) ,  mouse  Cyp19a1-Fw 
5′-TGGCAAGCTCTCCTCATCAA-3′ , Cyp19a1-Rev 5′ -TCTCCACGTCTCTCAGCGA-3′ (200 Bp amplicon), 
mouse 18S-Fw 5′ -CGCCGCTAGAGGTGAAATTC-3′ , 18S-Rev 5′-TTGGCAAATGCTTTCGCTC-3′ . All prim-
ers were designed using NCBI Primer-BLAST software to hybridize to different exons and generate a single 
amplicon in melting curve assays. Gene expression was quantified using the relative (Δ Δ CT) method with nor-
malization to the levels of 18S ribosomal RNA.
Other in vivo procedures. Mice were weighed using electronic scales. Anogenital distance was measured 
by an investigator blinded to genotype using a 0.1 mm Vernier caliper (Scienceware,Wayne, NJ, USA) with the 
median value of 5 measurements recorded. Glucose and insulin tolerance testing was performed after 16 or 6 h 
fasting and i.p. injection of 2.5 mg glucose or 0.75 mU of insulin/g body weight, respectively. Glycemia was meas-
ured using Accu-Check Aviva glucostrips. Whole body (minus head) lean, fat and bone mass was determined by 
in vivo dual energy X-ray absorptiometry using the PIXImus mouse densitometer (Lunar Corp) with an ultrahigh 
resolution (0.18 × 0.18 pixels, 1.6 line pairs/mm) and software v1.45.
Bone microCT and homogenization. Femurs and L5 vertebra were scanned using a Skyscan 1172 
ex vivo microCT (Brüker, Kontich, Belgium) with 50 kV, 200 μ A, 5 μ m resolution, 0.5 mm aluminum filter and 
0.6° angular rotation step settings, and analyzed using NRecon software as described previously53.
For intraskeletal E2 measurements, bilateral femurs, tibias and humeri were dissected, cleaned of soft tissue 
and snap frozen in liquid N2. Pools of 200–300 mg were homogenized using CKMix50-R tubes on a Precellys 24 
homogenizer (Bertin Technologies, Montigny le Bretonneux, France). Methanol, water and internal standards 
were added and LC-MS/MS performed as described above for serum samples.
Statistical analyses. Differences in continuous measures between two or more groups were analyzed by 
unpaired t-test (or Mann-Whitney U-test if variances were unequal) or ANOVA with Dunett’s post-test, respec-
tively. Two-way ANOVA with Bonferroni post-test was used to examine genotype-by-treatment interactions. 
Mean and standard error (SEM) are shown in all graphs unless specified otherwise. Analyses were performed 
using Graphpad Prism v5.04, and two-tailed P < 0.05 was considered significant.
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